Introduction Warfarin and dabigatran are used to prevent thromboembolism in patients with
atrial fibrillation (AF). Although these medications can effectively prevent ischemic stroke …

Background Oral anticoagulation is the mainstay of stroke prevention in atrial fibrillation
(AF), but must be balanced against the associated bleeding risk. Several risk scores have …

Aim When assessing bleeding risk in patients with atrial fibrillation (AF), risk stratification is
often based on the baseline risks. We aimed to investigate changes in bleeding risk factors …

Objectives Current international guidelines advocate the application of bleeding risk scores
only to identify modifiable risk factors, but not to withhold treatment in patients at high risk of …

Background: Atrial fibrillation (Afib) patients are at an increased risk of stroke. Patients at
moderate to high risk of stroke typically receive antithrombotics, placing them at an …

Abstract Funding Acknowledgements Type of funding sources: None. Objectives This study
aimed to validate different bleeding scoring systems including HAS-BELD score and other …

BACKGROUND: Current clinical decision tools for assessing bleeding risk in individuals
with atrial fibrillation (AF) have limited performance and were developed for individuals …

Background Oral anticoagulant drugs are proven to prevent thromboembolism in patients
with atrial fibrillation (AF). To date, HAS‐BLED score is used to assess bleeding risk. This …

Background Simple bleeding risk scores have been proposed to predict bleeding events, in
patients anticoagulated using non-warfarin anticoagulants. We compared the relative …

Background Patients with atrial fibrillation (AF) treated with oral anticoagulants may be
exposed to an increased risk of bleeding events. The HAS‐BLED (Hypertension, Abnormal …